## Rohit Shankar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2961682/publications.pdf

Version: 2024-02-01

153 papers 1,779 citations

361045 20 h-index 32 g-index

160 all docs

160 docs citations

160 times ranked 1626 citing authors

#	Article	IF	CITATIONS
1	Sudden unexpected death in epilepsy (SUDEP): Development of a safety checklist. Seizure: the Journal of the British Epilepsy Association, 2013, 22, 812-817.	0.9	82
2	Safe and sound? A systematic literature review of seizure detection methods for personal use. Seizure: the Journal of the British Epilepsy Association, 2016, 36, 4-15.	0.9	79
3	Sudden unexpected death in epilepsy (SUDEP): what every neurologist should know. Epileptic Disorders, 2017, 19, 1-9.	0.7	79
4	Does intellectual disability increase sudden unexpected death in epilepsy (SUDEP) risk?. Seizure: the Journal of the British Epilepsy Association, 2015, 25, 112-116.	0.9	73
5	Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data. Epilepsia, 2018, 59, 1727-1739.	2.6	67
6	COVID-19 deaths in people with intellectual disability in the UK and Ireland: descriptive study. BJPsych Open, 2020, 6, e123.	0.3	59
7	A community study in Cornwall UK of sudden unexpected death in epilepsy (SUDEP) in a 9-year population sample. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 382-385.	0.9	46
8	Managing antiâ€epileptic drug treatment in adult patients with intellectual disability: a serious conundrum. European Journal of Neurology, 2016, 23, 1152-1157.	1.7	37
9	Priority concerns for people with intellectual and developmental disabilities during the COVID-19 pandemic. BJPsych Open, 2020, 6, e128.	0.3	36
10	Attitudes Toward Psychiatry Among Final-Year Medical Students in Kumasi, Ghana. Academic Psychiatry, 2009, 33, 71-75.	0.4	30
11	A difficult combination: chronic physical illness, depression, and pain. British Journal of General Practice, 2014, 64, 440-441.	0.7	30
12	Steps to prevent SUDEP: the validity of risk factors in the SUDEP and seizure safety checklist: a case control study. Journal of Neurology, 2016, 263, 1840-1846.	1.8	30
13	Chromosomal microarray testing in adults with intellectual disability presenting with comorbid psychiatric disorders. European Journal of Human Genetics, 2017, 25, 66-72.	1.4	30
14	Identifying and mitigating Sudden Unexpected Death in Epilepsy (SUDEP) risk factors. Expert Review of Neurotherapeutics, 2018, 18, 265-274.	1.4	30
15	Comparison of the Simplexa FluA/B & Direct Assay and Laboratory-Developed Real-Time PCR Assays for Detection of Respiratory Virus. Journal of Clinical Microbiology, 2013, 51, 3883-3885.	1.8	27
16	Retention of perampanel in adults with pharmacoresistant epilepsy at a single tertiary care center. Epilepsy and Behavior, 2017, 73, 106-110.	0.9	26
17	Decreasing the risk of sudden unexpected death in epilepsy: structured communication of risk factors for premature mortality in people with epilepsy. European Journal of Neurology, 2018, 25, 1121-1127.	1.7	26
18	Under representation of people with epilepsy and intellectual disability in research. PLoS ONE, 2018, 13, e0198261.	1.1	26

#	Article	IF	Citations
19	A structured programme to withdraw antipsychotics among adults with intellectual disabilities: The Cornwall experience. Journal of Applied Research in Intellectual Disabilities, 2019, 32, 1389-1400.	1.3	24
20	Exploring the Evidence for Broad-Spectrum Effectiveness of Perampanel: A Systematic Review of Clinical Data in Generalised Seizures. CNS Drugs, 2021, 35, 821-837.	2.7	24
21	Perampanel in the general population and in people with intellectual disability: Differing responses. Seizure: the Journal of the British Epilepsy Association, 2017, 49, 30-35.	0.9	21
22	UK psychiatrists' experience of withdrawal of antipsychotics prescribed for challenging behaviours in adults with intellectual disabilities and/or autism. BJPsych Open, 2020, 6, e112.	0.3	21
23	Developing an Evidence-Based Epilepsy Risk Assessment eHealth Solution: From Concept to Market. JMIR Research Protocols, 2016, 5, e82.	0.5	20
24	Therapeutic use of serious games in mental health: scoping review. BJPsych Open, 2022, 8, e37.	0.3	20
25	Quality improvement in the management of people with epilepsy and intellectual disability: the development of clinical guidance. Expert Opinion on Pharmacotherapy, 2020, 21, 173-181.	0.9	19
26	Epilepsy, an orphan disorder within the neurodevelopmental family. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1245-1247.	0.9	19
27	Stopping, rationalising or optimising antipsychotic drug treatment in people with intellectual disability and/or autism. Drug and Therapeutics Bulletin, 2019, 57, 10-13.	0.3	18
28	Case report: Vagal nerve stimulation and late onset asystole. Seizure: the Journal of the British Epilepsy Association, 2013, 22, 312-314.	0.9	17
29	Neuromodulation of autism spectrum disorders using vagal nerve stimulation. Journal of Clinical Neuroscience, 2019, 63, 8-12.	0.8	17
30	Can technology help reduce risk of harm in patients with epilepsy?. British Journal of General Practice, 2015, 65, 448-449.	0.7	16
31	Sudden unexpected death in epilepsy in children: a focused review of incidence and risk factors. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1064-1070.	0.9	16
32	Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study. Journal of Neurology, 2022, 269, 2750-2760.	1.8	16
33	Efficacy and safety of VNS therapy or continued medication management for treatment of adults with drug-resistant epilepsy: systematic review and meta-analysis. Journal of Neurology, 2022, 269, 2874-2891.	1.8	16
34	Epilepsy in adults with neurodevelopmental disability ―what every neurologist should know. Epileptic Disorders, 2022, 24, 9-25.	0.7	16
35	The provision of care to adults with an intellectual disability in the UK. A Special report from the intellectual disability UK chapter ILAE. Seizure: the Journal of the British Epilepsy Association, 2018, 56, 41-46.	0.9	15
36	Digital Care in Epilepsy: A Conceptual Framework for Technological Therapies. Frontiers in Neurology, 2018, 9, 99.	1.1	15

#	Article	IF	Citations
37	Reducing the Risk of Sudden Unexpected Death in Epilepsy (SUDEP). Current Treatment Options in Neurology, 2018, 20, 40.	0.7	15
38	Bridging the gap of risk communication and management using the SUDEP and Seizure Safety Checklist. Epilepsy and Behavior, 2020, 103, 106419.	0.9	15
39	Clinical governance: risk assessment in SUDEP. Clinical Governance, 2013, 18, 325-331.	0.4	14
40	Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events. Epilepsy and Behavior, 2018, 80, 365-369.	0.9	14
41	Borderline personality disorder and sensory processing impairment. Progress in Neurology and Psychiatry, 2009, 13, 10-16.	0.4	13
42	Pseudocataplexy and Transient Functional Paralysis: A Spectrum of Psychogenic Motor Disorder. Journal of Neuropsychiatry and Clinical Neurosciences, 2010, 22, 445-450.	0.9	13
43	Modified Attitudes to Psychiatry Scale Created Using Principal-Components Analysis. Academic Psychiatry, 2011, 35, 360-4.	0.4	13
44	Mental health professionals and media professionals: a survey of attitudes towards one another. Journal of Mental Health, 2017, 26, 464-470.	1.0	13
45	Valproate risk formâ€"Surveying 215 clinicians involving 4775 encounters. Acta Neurologica Scandinavica, 2020, 141, 483-490.	1.0	13
46	Frequency and factors associated with emergency department attendance for people with epilepsy in a rural UK population. Epilepsy and Behavior, 2017, 68, 192-195.	0.9	12
47	Challenges and pitfalls of antipsychotic prescribing in people with learning disability. British Journal of General Practice, 2017, 67, 372-373.	0.7	12
48	A public health approach to reducing health inequalities among adults with autism. British Journal of General Practice, 2019, 69, 534-535.	0.7	12
49	Seizure and Sudden Unexpected Death in Epilepsy (SUDEP) characteristics in an urban UK intellectual disability service. Seizure: the Journal of the British Epilepsy Association, 2020, 80, 18-23.	0.9	12
50	Keeping patients with epilepsy safe: a surmountable challenge?. BMJ Quality Improvement Reports, 2015, 4, u208167.w3252.	0.8	11
51	Sudden unexpected death in epilepsy: measures to reduce risk. Practical Neurology, 2017, 17, 13-20.	0.5	11
52	The use of psychotropic medication for people with intellectual disabilities and behaviours that challenge in the context of a community multidisciplinary team approach. British Journal of Learning Disabilities, 2018, 46, 4-9.	0.8	11
53	Improving knowledge of psychotropic prescribing in people with Intellectual Disability in primary care. PLoS ONE, 2018, 13, e0204178.	1.1	11
54	Valproate, women, and exceptional circumstances. BMJ: British Medical Journal, 2018, 362, k3625.	2.4	11

#	Article	IF	Citations
55	Valproate MHRA Guidance: Limitations and Opportunities. Frontiers in Neurology, 2019, 10, 139.	1.1	11
56	Lacosamide in the general population and in people with intellectual disability: Similar responses?. Seizure: the Journal of the British Epilepsy Association, 2020, 76, 161-166.	0.9	11
57	Antidepressant prescribing for adult people with an intellectual disability living in England. British Journal of Psychiatry, 2022, 221, 488-493.	1.7	11
58	Has the Time Come to Stratify and Score SUDEP Risk to Inform People With Epilepsy of Their Changes in Safety?. Frontiers in Neurology, 2018, 9, 281.	1.1	10
59	SUDEP and seizure safety communication: Assessing if people hear and act. Epilepsy and Behavior, 2018, 86, 200-203.	0.9	10
60	New anti-seizure medication for elderly epileptic patients. Expert Opinion on Pharmacotherapy, 2019, 20, 1601-1608.	0.9	10
61	The Current Provision of Mental Health Services for Individuals with Mild Intellectual Disability: A Scoping Review. Journal of Mental Health Research in Intellectual Disabilities, 2022, 15, 49-75.	1.3	10
62	Valproate and the Pregnancy Prevention Programme: exceptional circumstances. British Journal of General Practice, 2019, 69, 166-167.	0.7	9
63	Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability. Expert Opinion on Pharmacotherapy, 2020, 21, 1897-1913.	0.9	9
64	Psychiatry and neurodevelopmental disorders: experts by experience, clinical care and research. British Journal of Psychiatry, 2021, 218, 1-3.	1.7	9
65	COVID-19 pandemic impact on psychotropic prescribing for adults with intellectual disability: an observational study in English specialist community services. BJPsych Open, 2022, 8, e7.	0.3	9
66	Discharging inpatients with intellectual disability from secure to community services: risk assessment and management considerations. Advances in Mental Health and Intellectual Disabilities, 2017, 11, 98-109.	0.7	8
67	Desperately seeking outcomes: quantifying the effectiveness of community mental healthcare using Health of the Nation Outcome Scales. BJPsych Open, 2018, 4, 91-94.	0.3	8
68	Head first $\hat{a} \in \mathbb{C}$ Review of epilepsy head injury risk and protection. Seizure: the Journal of the British Epilepsy Association, 2019, 71, 66-79.	0.9	8
69	Epilepsy, anti-seizure medication, intellectual disability and challenging behaviour – Everyone's business, no one's priority. Seizure: the Journal of the British Epilepsy Association, 2020, 81, 111-116.	0.9	8
70	European perspective of perampanel response in people with Intellectual Disability. Acta Neurologica Scandinavica, 2020, 142, 255-259.	1.0	8
71	The evidence for switching dibenzazepines in people with epilepsy. Acta Neurologica Scandinavica, 2020, 142, 121-130.	1.0	8
72	An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England. Journal of Medical Economics, 2021, 24, 1037-1051.	1.0	8

#	Article	IF	CITATIONS
73	People with epilepsy and intellectual disability: More than a sum of two conditions. Epilepsy and Behavior, 2021, 124, 108355.	0.9	8
74	Tackling increased risks in older adults with intellectual disability and epilepsy: Data from a national multicentre cohort study. Seizure: the Journal of the British Epilepsy Association, 2022, 101, 15-21.	0.9	8
75	Pharmacological treatment of schizophrenia - a review of progress. Progress in Neurology and Psychiatry, 2016, 20, 28-35.	0.4	7
76	Depression and pain: the need for a new screening tool. Progress in Neurology and Psychiatry, 2016, 20, 26-32.	0.4	7
77	Epilepsy awareness and emergency rescue training: Ignorance is bliss!. Epilepsy and Behavior, 2017, 70, 212-216.	0.9	7
78	General practitioners' and psychiatrists' attitudes towards antidepressant withdrawal. BJPsych Open, 2020, 6, e64.	0.3	7
79	Exploring epilepsy attendance at the emergency department and interventions which may reduce unnecessary attendances: A scoping review. Seizure: the Journal of the British Epilepsy Association, 2020, 76, 39-46.	0.9	7
80	Patterns of comorbidity and psychopharmacology in adults with intellectual disability and attention deficit hyperactivity disorder: an UK national cross-sectional audit. Expert Opinion on Pharmacotherapy, 2021, 22, 1071-1078.	0.9	7
81	Current practice and adaptations being made for people with autism admitted to in-patient psychiatric services across the UK. BJPsych Open, 2021, 7, e102.	0.3	7
82	Bone health, intellectual disability and epilepsy: An observational communityâ€based study. Acta Neurologica Scandinavica, 2022, 145, 753-761.	1.0	7
83	A review of the pharmacotherapeutic considerations for managing epilepsy in people with autism. Expert Opinion on Pharmacotherapy, 2022, 23, 841-851.	0.9	7
84	Post-COVID syndrome and adults with intellectual disability: another vulnerable population forgotten?. British Journal of Psychiatry, 2023, 222, 1-3.	1.7	7
85	Monitoring nocturnal seizure in vulnerable patients. Learning Disability Practice, 2013, 16, 36-38.	0.1	6
86	Going down the tubes! Impact on seizure control of antiepileptic medication given via percutaneous feeding tubes. Epilepsy and Behavior, 2017, 74, 114-118.	0.9	6
87	Creating Capable Communities for People with Intellectual Disabilities: Challenges and Opportunities. Journal of Mental Health Research in Intellectual Disabilities, 2020, 13, 174-200.	1.3	6
88	EEG Markers in Emotionally Unstable Personality Disorderâ€"A Possible Outcome Measure for Neurofeedback: A Narrative Review. Clinical EEG and Neuroscience, 2021, 52, 254-273.	0.9	6
89	Attention-deficit hyperactivity disorder in people with intellectual disability: statistical approach to developing a bespoke screening tool. BJPsych Open, 2021, 7, e187.	0.3	6
90	Impact of COVID-19 on mental health research: is this the breaking point?. British Journal of Psychiatry, 2022, 220, 254-256.	1.7	6

#	Article	IF	Citations
91	An 8â€year study of admissions and discharges to a specialist intellectual disability inpatient unit. Journal of Applied Research in Intellectual Disabilities, 2022, 35, 569-576.	1.3	6
92	Patient- and carer-held health records: can they improve annual health checks for patients with learning disability?. British Journal of General Practice, 2016, 66, 210-212.	0.7	5
93	What happens when 55% of acute psychiatric beds are closed in six days: an unexpected naturalistic observational study. JRSM Open, 2016, 7, 205427041664928.	0.2	5
94	Local radio to promote mental health awareness: a public health initiative. BJPsych Open, 2019, 5, e60.	0.3	5
95	Eslicarbazepine acetate response in intellectual disability population versus general population. Acta Neurologica Scandinavica, 2021, 143, 256-260.	1.0	5
96	International clinician perspectives on pandemic-associated stress in supporting people with intellectual and developmental disabilities. BJPsych Open, 2022, 8, e84.	0.3	5
97	An audit of the quality of reports to Mental Health Review Tribunals. Medicine, Science and the Law, 2008, 48, 221-224.	0.6	4
98	Awareness, attitudes, skills and training needs of psychiatrists working with adults with intellectual disability in managing epilepsy. Seizure: the Journal of the British Epilepsy Association, 2018, 63, 105-112.	0.9	4
99	Bespoke STOMP training for learning disability teams—Does it work?. British Journal of Learning Disabilities, 2019, 47, 181-187.	0.8	4
100	Investigative practice into sudden death in epilepsy: A global survey. Acta Neurologica Scandinavica, 2019, 139, 476-482.	1.0	4
101	Keep safe: The when, why and how of epilepsy risk communication. Seizure: the Journal of the British Epilepsy Association, 2020, 78, 136-149.	0.9	4
102	Optimising medicines use in older adults with intellectual disability who have epilepsy: challenges and perspectives. Therapeutic Advances in Drug Safety, 2021, 12, 204209862110251.	1.0	4
103	Eye Movement Desensitisation and Reprocessing Therapy for People with Intellectual Disability in the Treatment of Emotional Trauma and Post Traumatic Stress Disorder: A Scoping Review. Journal of Mental Health Research in Intellectual Disabilities, 2021, 14, 237-284.	1.3	4
104	Oro-mucosal midazolam maleate: Use and effectiveness in adults with epilepsy in the UK. Epilepsy and Behavior, 2021, 123, 108242.	0.9	4
105	Epilepsy emergency rescue training. BMJ Quality Improvement Reports, 2015, 4, u208167.w3566.	0.8	3
106	Improving epilepsy management with EpSMon: A Templar to highlight the multifaceted challenges of incorporating digital technologies into routine clinical practice. Epilepsy and Behavior, 2020, 103, 106514.	0.9	3
107	Awareness of bone health risks in people with epilepsy and intellectual disability. British Journal of Learning Disabilities, 2020, 48, 224-231.	0.8	3
108	An evaluation of the effectiveness of perampanel in people with epilepsy who have previously undergone resective surgery and/or implantation of a vagal nerve stimulator. Epilepsy and Behavior, 2021, 116, 107738.	0.9	3

#	Article	IF	CITATIONS
109	A Review of Network and Computer Analysis of Epileptiform Discharge Free EEG to Characterize and Detect Epilepsy. Clinical EEG and Neuroscience, 2022, 53, 74-78.	0.9	3
110	Remote Electroencephalography Monitoring of Epilepsy in Adults: Protocol for a Scoping Review. JMIR Research Protocols, 2022, 11, e33812.	0.5	3
111	Seizures and emergency department: characteristics and factors of repeat adult attendees. Journal of Neurology, 2022, , 1.	1.8	3
112	Using medical education as a tool to train doctors as social innovators. BMJ Innovations, 2022, 8, 190-198.	1.0	3
113	Quality standards for community mental health teams. Psychiatric Bulletin, 2009, 33, 387-389.	0.3	2
114	A radio phone-in programme for mental health education and promotion. Progress in Neurology and Psychiatry, 2013, 17, 37-38.	0.4	2
115	Consent to contraceptive treatment among clients with epilepsy. Learning Disability Practice, 2013, 16, 27-30.	0.1	2
116	Managing clients placed far away from their communities. Learning Disability Practice, 2015, 18, 29-34.	0.1	2
117	Abnormal cortical asymmetry as a target for neuromodulation in neuropsychiatric disorders: A narrative review and concept proposal. Neuroscience and Biobehavioral Reviews, 2017, 83, 21-31.	2.9	2
118	Sudden Unexpected Death in Epilepsy (SUDEP) and seizure safety: Modifiable and non-modifiable risk factors differences between primary and secondary care. Epilepsy and Behavior, 2021, 115, 107637.	0.9	2
119	Valproate prescribing practices for women with intellectual disability across Europe. Acta Neurologica Scandinavica, 2021, 143, 56-61.	1.0	2
120	Perceptions about mental healthcare for people with epilepsy in Africa. Epilepsy and Behavior, 2022, 127, 108504.	0.9	2
121	Bone health in adults with epilepsy and intellectual disability. British Journal of General Practice, 2022, 72, 100-101.	0.7	2
122	Humanizing Health and Social Care Support for People With Intellectual and Developmental Disabilities: Protocol for a Scoping Review. JMIR Research Protocols, 2022, 11, e31720.	0.5	2
123	A comparison of suicide and undetermined deaths in Cornwall across national and local agencies. Medicine, Science and the Law, 2010, 50, 19-21.	0.6	1
124	Assessing Mental Capacity. InnovAiT, 2011, 4, 98-103.	0.0	1
125	Zero suicide southwest UK initiative–ÂSteps to mitigate suicide risk in local populations using quality improvement methodology and a whole life approach. European Psychiatry, 2017, 41, S402-S402.	0.1	1
126	Getting a balance between generalisation and specialisation in mental health services: a defence of general services. BJPsych Bulletin, 2018, 42, 229-232.	0.7	1

#	Article	IF	CITATIONS
127	Women's experiences of managing digitation: do we ask enough in primary care?. JRSM Open, 2018, 9, 205427041878361.	0.2	1
128	Differential attainment in undergraduate medical education: a systematic review. BJPsych Open, 2021, 7, S27-S28.	0.3	1
129	Oxygen for seizures, more questions than answers: A scoping review. Acta Neurologica Scandinavica, 2021, 144, 719-729.	1.0	1
130	UK framework for basic epilepsy training and oromucosal midazolam administration. Epilepsy and Behavior, 2021, 122, 108180.	0.9	1
131	Epilepsy in People with Intellectual Disability. , 2020, , 221-234.		1
132	Helping clinicians improve the health of their communities: The Beddoes Fellows Programme. Journal of Behavioral Health, 2012, 1, 167.	0.1	1
133	Intellectual Disability and Epilepsy. , 2019, , 187-202.		1
134	A critique of NHS culture as applied to psychiatry. British Journal of Health Care Management, 2008, 14, 147-152.	0.1	0
135	How to ensure people with multiple diagnoses make the right decisions. Learning Disability Practice, 2012, 15, 27-30.	0.1	0
136	Sensory processing in people with Asperger syndrome. Learning Disability Practice, 2013, 16, 22-27.	0.1	0
137	Mental health and CPD: could videoconferencing be a way forward?. Progress in Neurology and Psychiatry, 2015, 19, 25-26.	0.4	0
138	Successful transfers to out-of-area placements. Learning Disability Practice, 2016, 19, 18-22.	0.1	0
139	Abnormal cortical asymmetry as a target for neuromodulation in neuropsychiatric disorders: A conceptual proposal. Brain Stimulation, 2017, 10, 436.	0.7	0
140	Re: Reply to Drs. Joob and Wiwanikit. Epilepsy and Behavior, 2017, 75, 275.	0.9	0
141	A Simple Composite Dynamic Digital Tool to Communicate Complex Physical and Mental Health needs and Measure Outcomes: The Cornwall Health Radar. European Psychiatry, 2017, 41, S93-S94.	0.1	0
142	An evidenced based checklist to support anti-dementia medication withdrawal in people with down syndrome (DS), intellectual disability (Id) and dementia. European Psychiatry, 2017, 41, S599-S599.	0.1	0
143	Does a Bespoke Intellectual Disability (ID) Epilepsy Service Reduce Mortality? A 11 Year Study of Sudden Unexpected Death in Epilepsy (SUDEP) in Cornwall UK. European Psychiatry, 2017, 41, S161-S161.	0.1	0
144	An evidencedâ€based strategy for timely delivery of clinical letters. Progress in Neurology and Psychiatry, 2017, 21, 11-14.	0.4	0

#	Article	IF	CITATIONS
145	PO049â€What drives ed attendance in people with epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A24.4-A25.	0.9	0
146	PO048â€Sudep and epilepsy risk – epsmon an e-health assessment tool. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A24.3-A24.	0.9	0
147	Do the severity of Intellectual Disability and /or the presence of neurodevelopmental disorders influence the onset of dementia in people with Down syndrome?. Journal of Mental Health Research in Intellectual Disabilities, 2020, 13, 322-342.	1.3	O
148	Transforming care in Cornwall: A review of the quality of the lives of people with learning disabilities a decade postâ€discharge from hospital. British Journal of Learning Disabilities, 2020, 48, 315-322.	0.8	0
149	The neurology–psychiatry interface in epilepsy. Irish Journal of Psychological Medicine, 2021, 38, 9-15.	0.7	O
150	Community Monitoring of Health Parameters in People with Intellectual Disabilities Prescribed Lithium. Journal of Mental Health Research in Intellectual Disabilities, 2021, 14, 159-173.	1.3	0
151	Mental health and epilepsy: A survey exploring perspectives of healthcare providers in Sub-Saharan Africa. Journal of the Neurological Sciences, 2021, 429, 119217.	0.3	O
152	The Use of Antiepileptic Medication in Adults with Intellectual Disabilities: A Serious Conundrum. , 2016, , 115-143.		0
153	A Scoping Review of Differential Attainment in Undergraduate Medicine. Sushruta Journal of Health Policy & Opinions, 2020, 13, 1-10.	0.1	O